This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Immunoglobulin-Gene Rearrangements as Unique Clonal Markers in Human Lymphoid Neoplasms

List of authors.
  • Andrew Arnold, M.D.,
  • Jeffrey Cossman, M.D.,
  • Ajay Bakhshi, M.B., B.S.,
  • Elaine S. Jaffe, M.D.,
  • Thomas A. Waldmann, M.D.,
  • and Stanley J. Korsmeyer, M.D.

Abstract

Immunoglobulin genes in their germ-line form are separated DNA subsegments that must be joined by means of recombinations during B-cell development. Individual immunoglobulin-gene rearrangements are specific for a given B cell and its progeny. We show that the detection of such gene rearrangements by Southern hybridization provides a sensitive marker for both clonality and B-cell lineage within lymphoid tissues lacking expression of definitive surface phenotypes. We have used these genetic markers in three ways: to establish a diagnosis of lymphoma in a neoplastic disorder of uncertain cell type, to show that some lymphomas that were previously classified as being of T-cell type in fact contain monoclonal B cells, and to detect clonal B-cell populations within lymphomatous tissues of uncertain immunotype and within an atypical lymphofollicular hyperplasia having no other clonal surface markers. These sensitive and unique indicators of clonality located directly at the DNA level are capable of providing insights into the cellular origin, early detection, and natural history of neoplasia. (N Engl J Med 1983; 309: 1593–9.)

Funding and Disclosures

We are indebted to Drs. John D. Minna, Arnold B. Rabson, and Jeffrey Schlom for generously contributing DNA from various carcinoma tissues used as controls in this study.

Author Affiliations

From the Metabolism Branch and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health. Address reprint requests to Dr. Arnold at Bldg. 10, Rm. 4N–110, National Institutes of Health, Bethesda, MD 20205.

Print Subscriber? Activate your online access.